Evidence map›Paper›PMID 39976248›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2025

Discovery of a selective and reversible LSD1 inhibitor with potent anticancer effects

Xiao-Song Zhang, Jin-Zhan Liu, Ying-Ying Mei, Meng Zhang, Li-Wei Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiao-Song ZhangXinxiang Central Hospital, The Fourth Clinical College of Xinxiang Medical University, Xinxiang, China.
Jin-Zhan LiuXinxiang Central Hospital, The Fourth Clinical College of Xinxiang Medical University, Xinxiang, China.
Ying-Ying MeiXinxiang Central Hospital, The Fourth Clinical College of Xinxiang Medical University, Xinxiang, China.
Meng ZhangXinxiang Central Hospital, The Fourth Clinical College of Xinxiang Medical University, Xinxiang, China.
Li-Wei SunXinxiang Central Hospital, The Fourth Clinical College of Xinxiang Medical University, Xinxiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lysine-specific demethylase 1 (LSD1) is abnormally overexpressed in various tumour tissues of patients and has been an attractive anticancer target. In this work, a potent LSD1 inhibitor (compound

Indexed as

Antineoplastic AgentsDrug DiscoveryEnzyme InhibitorsHistone DemethylasesAnimalsCell Line, TumorCell MovementCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMiceMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsEnzyme InhibitorsHistone DemethylasesKDM1A protein, humananti-liver cancer effectsepithelial–mesenchymal transitionH3K4me1/2LSD1migration

Identifiers

PMID39976248
PMCPMC11843658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.